IGLV7-43 (V3-2) as A Potential Drug Target Or Biomarker (G28776)

Target Name: IGLV7-43

NCBI ID: G28776

IGLV7-43

Other Name(s): V3-2 | IGLV743 | immunoglobulin lambda variable 7-43 | Immunoglobulin lambda variable 7-43

IGLV7-43 (V3-2) as A Potential Drug Target Or Biomarker

IGLV7-43 (V3-2) is a protein that is expressed in the human placenta and has been shown to play a role in the development and progression of various diseases, including cancer. Because of its unique structure and biological activity, it is A potential drug target (or biomarker).

IGLV7-43 (V3-2) is a full-length protein whose encoding gene is located at human chromosome 1p36.1. The protein consists of 794 amino acids and has a molecular weight of 10.9 kDa. IGLV7-43 (V3-2) is located in the cytoplasm of cells and is expressed in a variety of tissues, including neural tissue, liver and kidney.

Research shows that IGLV7-43 (V3-2) plays an important role in a variety of diseases. For example, in breast cancer, IGLV7-43 (V3-2) is expressed at higher levels and is associated with breast cancer progression and invasiveness. In colorectal cancer, another common cancer, higher expression levels of IGLV7-43 (V3-2) are also associated with disease progression and patient survival.

In addition, studies have shown that IGLV7-43(V3-2) is also associated with a variety of other diseases and clinical processes. For example, in Alzheimer's disease, higher expression levels of IGLV7-43 (V3-2) are associated with disease progression and cognitive decline. In diabetes, IGLV7-43 (V3-2) expression levels are also higher and are associated with disease progression and glycemic control.

Based on the above studies, IGLV7-43 (V3-2) is considered a potential drug target (or biomarker). Currently, researchers are exploring the role of IGLV7-43 (V3-2) in treating various diseases, including breast cancer, colorectal cancer, Alzheimer's disease, and diabetes.

In addition, since IGLV7-43(V3-2) is expressed in various diseases, it may also become an important biomarker. This protein can be used to monitor disease progression and treatment effects, providing patients with better treatment options.

In summary, IGLV7-43 (V3-2) is a potential drug target (or biomarker) that plays an important role in a variety of diseases. Through further research, new clues can be provided for the development of effective drugs to treat various diseases.

Protein Name: Immunoglobulin Lambda Variable 7-43

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

The "IGLV7-43 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV7-43 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets